If approved, TLX250-CDx will become the first commercially available imaging agent to accurately and non-invasively diagnose and characterize clear cell renal cell carcinoma (ccRCC), the most common ...
China’s DeepSeek shocked the world by delivering unexpected innovation at an unbelievable price. But this disruptive trend ...
Stem cell research and regenerative medicine are growing markets in the life science sector, and the top stem cell companies ...
A New Drug Application has been accepted seeking accelerated approval for dordaviprone for patients with recurrent H3 ...
There are now many colorectal cancer screening options, but gastroenterologists say a colonoscopy is still necessary.
Boehringer Ingelheim has prevailed in the trial of two lawsuits claiming that its discontinued heartburn drug Zantac caused ...
The FDA accepted for priority review a supplemental Biologics License Application for Keytruda for resectable locally ...
The FDA's new standards for foods before they can be labeled as "healthy" on their packaging will go into effect about two ...
Millions of American women are at high risk for breast cancer, but their insurance does not cover the costs of extra ...
Merck & Co. has won U.S. Food and Drug Administration priority review for its application seeking expanded use of its blockbuster cancer drug Keytruda in certain patients with head and neck cancer.
A jury found Naheed Mangi replaced patient medical data with erroneous information, insults about former boss.